Clinical Research Directory
Browse clinical research sites, groups, and studies.
CINC424A2X01B Rollover Protocol
Sponsor: Novartis Pharmaceuticals
Summary
This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.
Official title: Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies
Key Details
Gender
All
Age Range
1 Month - 100 Years
Study Type
INTERVENTIONAL
Enrollment
279
Start Date
2015-03-05
Completion Date
2027-09-16
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
ruxolitinib
ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study
panobinostat
panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study
Locations (97)
Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Novartis Investigative Site
Herston, Queensland, Australia
Novartis Investigative Site
Wooloongabba, Queensland, Australia
Novartis Investigative Site
Bedford Park, South Australia, Australia
Novartis Investigative Site
Box Hill, Victoria, Australia
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Franston, Victoria, Australia
Novartis Investigative Site
Perth, Western Australia, Australia
Novartis Investigative Site
St Leonards, Australia
Novartis Investigative Site
Leuven, Vlaams Brabant, Belgium
Novartis Investigative Site
Antwerp, Belgium
Novartis Investigative Site
Bruges, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Viña del Mar, Región de Valparaíso, Chile
Novartis Investigative Site
Santiago, RM, Chile
Novartis Investigative Site
Santiago, Chile
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Jena, Thuringia, Germany
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Pátrai, Greece
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Kaposvár, Hungary
Novartis Investigative Site
Kecskemét, Hungary
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Szombathely, Hungary
Novartis Investigative Site
Pune, Maharashtra, India
Novartis Investigative Site
Afula, Israel
Novartis Investigative Site
Jerusalem, Israel
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Bari, BA, Italy
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Brescia, BS, Italy
Novartis Investigative Site
San Giovanni Rotondo, FG, Italy
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Palermo, PA, Italy
Novartis Investigative Site
Pavia, PV, Italy
Novartis Investigative Site
Reggio Calabria, RC, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Orbassano, TO, Italy
Novartis Investigative Site
Varese, VA, Italy
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Isehara, Kanagawa, Japan
Novartis Investigative Site
Suita, Osaka, Japan
Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Osaka, Japan
Novartis Investigative Site
Beirut, Lebanon
Novartis Investigative Site
Monterrey, Nuevo León, Mexico
Novartis Investigative Site
Gliwice, Silesian Voivodeship, Poland
Novartis Investigative Site
Wroclaw, Poland
Novartis Investigative Site
Lisbon, Portugal
Novartis Investigative Site
Lisbon, Portugal
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Petrozavodsk, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Pretoria, Gauteng, South Africa
Novartis Investigative Site
Soweto, Gauteng, South Africa
Novartis Investigative Site
Cape Town, Western, South Africa
Novartis Investigative Site
Pretoria, South Africa
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Pamplona, Navarre, Spain
Novartis Investigative Site
Salamanca, Spain
Novartis Investigative Site
Huddinge, Sweden
Novartis Investigative Site
Luleå, Sweden
Novartis Investigative Site
Lund, Sweden
Novartis Investigative Site
Uddevalla, Sweden
Novartis Investigative Site
Bangkok, Thailand
Novartis Investigative Site
Istanbul, Fatih, Turkey (Türkiye)
Novartis Investigative Site
Kayseri, Melikgazi, Turkey (Türkiye)
Novartis Investigative Site
Ankara, Sihhiye-Altindag, Turkey (Türkiye)
Novartis Investigative Site
Izmir, Turkey (Türkiye)